Short answer
Biogen (BIIB) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Biogen reported third-quarter fiscal 2026 results for the period ended September 30, 2026.
Biogen 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Biogen reported third-quarter fiscal 2026 results for the period ended September 30, 2026
- Full financial results and management commentary are contained in Exhibit 99.1, the accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $2.8B, up 11% year over year, signaling renewed growth led by the Growth Portfolio and Apellis products
- Growth Portfolio revenue $1.26B, up 49%, now 63% of Core Pharmaceutical revenue
- Non-GAAP EPS $2.62, burdened by $284M of acquired IPR&D, upfront and milestone expense
- GAAP diluted EPS $(0.14), reflecting transaction-related charges and a $20.6M net loss
- FY 2026 Non-GAAP EPS guidance raised to $12.20-$13.00, while net debt reached approximately $6.4B after Apellis-related financing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biogen 8-K filings
Get the next BIIB 8-K as it lands
Follow BIIB for push alerts, or ask the research agent what this filing means.